Concerns Rise Over Potential Overuse of Costly Cancer Medications
A recent commentary suggests that some cancer patients might be receiving larger doses and longer treatment periods of pricey drugs than necessary.
The piece argues that current prescribing practices could be leading to unnecessary exposure to high-cost cancer therapies. It points out that patients may be on extended regimens without clear benefit, raising questions about clinical and financial justification. The author also notes a recent fluctuation in Moderna's share price, attributing it to profit-taking by investors.
Why it matters
Overprescribing costly cancer drugs can strain patients financially and inflate healthcare expenses.
In this story
cancer patientsdrug dosingexpensive drugsModerna stockprofit-taking
